Q-omics provides the consensus-scored CDK8 profile across patient tissues and cancer cell-line models. CDK8 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, CDK8 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, CDK8 RNA expression shows 20,412 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight CESC, COAD, and UVM as cancer lineages where CDK8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDK8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDK8 survival associations across molecular data types. CDK8 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDK8 RNA expression–survival associations across cancer types. High CDK8 expression shows unfavorable associations in CESC, BRCA, MESO, LIHC, KICH and UVM. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for CDK8 RNA expression.
This table summarizes CDK8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CDK8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDK8 shows lower tumor expression in THCA and higher tumor expression in COAD, HNSC, LIHC, LUSC and LUAD. The COAD box plot shows higher CDK8 RNA expression in tumor versus normal tissue (log2 FC = +1.195, t-test p < 0.001).
This table shows molecular features associated with CDK8 in patient tissues and cancer cell lines. In patient samples, CDK8 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CDK8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
